/FRX.TO
FRX.TO Stock - Fennec Pharmaceuticals Inc.
Healthcare|BiotechnologyTSX
$10.63+2.31%
+$0.24 (+2.31%) • Dec 22
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.37
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.90
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $11.69
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for FRX.TO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$10.52 – $10.74
TARGET (TP)$12.22
STOP LOSS$9.78
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.75
52W High$13.83
52W Low$7.02
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $47.54M | $21.25M | $1.53M | N/A | $170,000 |
| Gross Profit | $44.35M | $19.99M | $1.45M | N/A | $170,000 |
| Gross Margin | 93.3% | 94.1% | 94.4% | N/A | 100.0% |
| Operating Income | $2.57M | $-12,771,000 | $-22,589,000 | $-17,223,000 | $-17,885,000 |
| Net Income | $-436,000 | $-16,045,000 | $-23,861,000 | $-17,456,000 | $-18,109,000 |
| Net Margin | -0.9% | -75.5% | -1554.5% | N/A | -10652.4% |
| EPS | $-0.02 | $-0.60 | $-0.91 | $-0.67 | $-0.76 |
Company Overview
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
FRX.TOBeat Rate
28%
Last 18 quarters
Avg Surprise
-45.2%
EPS vs Estimate
Beats / Misses
5/11
2 met exactly
Latest EPS
$-0.03
Q4 2025
EPS Surprise History
Q4 23
+40.8%
$-0.10vs$-0.16
Q1 24
-442.1%
$-0.13vs$-0.02
Q2 24
+818.6%
$0.56vs$-0.08
Q3 24
-728.8%
$-0.28vs$-0.03
Q4 24
-104.1%
$-0.29vs$-0.14
Q1 25
-20.2%
$-0.10vs$-0.09
Q2 25
+50.8%
$-0.06vs$-0.12
Q4 25
-141.7%
$-0.03vs$0.08
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 9, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | $0.08 | $-0.03 | -141.7% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.12 | $-0.06 | +50.8% | ✓ BEAT |
Q1 2025 | Mar 10, 2025 | $-0.09 | $-0.10 | -20.2% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.14 | $-0.29 | -104.1% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.03 | $-0.28 | -728.8% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.08 | $0.56 | +818.6% | ✓ BEAT |
Q1 2024 | Mar 21, 2024 | $-0.02 | $-0.13 | -442.1% | ✗ MISS |
Q4 2023 | Nov 6, 2023 | $-0.16 | $-0.10 | +40.8% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.21 | $-0.27 | -29.9% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.27 | $-0.31 | -13.2% | ✗ MISS |
Q1 2023 | Mar 29, 2023 | $-0.26 | $-0.26 | 0.0% | = MET |
Q4 2022 | Nov 11, 2022 | $-0.18 | $-0.31 | -72.2% | ✗ MISS |
Q3 2022 | Aug 12, 2022 | $-0.14 | $-0.19 | -35.7% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.14 | $-0.14 | 0.0% | = MET |
Q1 2022 | Feb 28, 2022 | $0.75 | $-0.18 | -124.0% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.17 | $-0.16 | +5.9% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-0.19 | $-0.15 | +21.1% | ✓ BEAT |
Q2 2021 | May 13, 2021 | $-0.13 | $-0.18 | -38.5% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about FRX.TO
What is FRX.TO's current stock price?
Fennec Pharmaceuticals Inc. (FRX.TO) is currently trading at $10.63 per share. The stock has moved +2.31% today.
What is the analyst price target for FRX.TO?
No analyst price targets are currently available for this stock.
What sector is Fennec Pharmaceuticals Inc. in?
Fennec Pharmaceuticals Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the TSX exchange.
What is FRX.TO's market cap?
Fennec Pharmaceuticals Inc. has a market capitalization of $0.29 billion, making it a small-cap company.
Does FRX.TO pay dividends?
No, Fennec Pharmaceuticals Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCYBN.NE
Cybin Inc.
$9.79
Mkt Cap: $0.2B
DR.TO
Medical Facilities Corporation
$15.48
Mkt Cap: $0.3B
EPRX.TO
Eupraxia Pharmaceuticals Inc.
$9.70
Mkt Cap: $0.3B
HBP.TO
Helix BioPharma Corp.
$2.29
Mkt Cap: $0.2B
HITI.V
High Tide Inc.
$3.86
Mkt Cap: $0.3B
NGEN.V
NervGen Pharma Corp.
$6.85
Mkt Cap: $0.5B
OGI.TO
OrganiGram Holdings Inc.
$2.64
Mkt Cap: $0.4B
PRN.TO
Profound Medical Corp.
$10.03
Mkt Cap: $0.3B
TSND.TO
TerrAscend Corp.
$1.00
Mkt Cap: $0.3B
WEED.TO
Canopy Growth Corporation
$1.84
Mkt Cap: $0.3B
Explore stocks similar to FRX.TO for comparison